Page 74 - Read Online

Martin et al. Microbiome Res Rep 2023;2:17 https://dx.doi.org/10.20517/mrr.2023.10 Page 11 of 13

Commun 2021;12:3254. DOI PubMed PMC
55. Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol 2019;16:35-56.
DOI PubMed
56. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and
metabolic disease. Genome Med 2016;8:42. DOI PubMed PMC
57. Vital M, Penton CR, Wang Q, et al. A gene-targeted approach to investigate the intestinal butyrate-producing bacterial community.
Microbiome 2013;1:8. DOI PubMed PMC
58. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS
Microbiol Lett 2009;294:1-8. DOI PubMed
59. O Sheridan P, Martin JC, Lawley TD, et al. Polysaccharide utilization loci and nutritional specialization in a dominant group of
butyrate-producing human colonic Firmicutes. Microb Genom 2016;2:e000043. DOI PubMed PMC
60. Qian Y, Lan F, Venturelli OS. Towards a deeper understanding of microbial communities: integrating experimental data with
dynamic models. Curr Opin Microbiol 2021;62:84-92. DOI PubMed PMC
61. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 2014;16:1024-33. DOI
PubMed PMC
62. Liu H, Wang J, He T, et al. Butyrate: a double-edged sword for health? Adv Nutr 2018;9:21-9. DOI PubMed PMC
63. Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with
cancer. Nat Commun 2020;11:2168. DOI PubMed PMC
64. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr 2004;134:479-82. DOI
PubMed
65. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75-84. DOI PubMed
66. Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ. Role of the microbiome in human development. Gut 2019;68:1108-
14. DOI PubMed PMC
67. Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue
Barriers 2017;5:e1373208. DOI PubMed PMC
68. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis
2015;26:26191. DOI PubMed PMC
69. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin
J Gastroenterol 2018;11:1-10. DOI PubMed
70. Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional
implications and recovery. Curr Opin Microbiol 2018;44:34-40. DOI PubMed PMC
71. Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E. Microbiome in colorectal cancer: how to get from meta-omics to
mechanism? Trends Microbiol 2020;28:401-23. DOI
72. Khan I, Bai Y, Zha L, et al. Mechanism of the gut microbiota colonization resistance and enteric pathogen infection. Front Cell Infect
Microbiol 2021;11:1273. DOI PubMed PMC
73. Diether NE, Willing BP. Microbial fermentation of dietary protein: an important factor in diet-microbe-host interaction.
Microorganisms 2019;7:19. DOI PubMed PMC
74. Isles NS, Mu A, Kwong JC, Howden BP, Stinear TP. Gut microbiome signatures and host colonization with multidrug-resistant
bacteria. Trends Microbiol 2022;30:853-65. DOI PubMed
75. Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem?
Front Microbiol 2016;7:455. DOI PubMed PMC
76. Sze MA, Schloss PD. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio 2016;7:e01018-16. DOI
PubMed PMC
77. Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in
inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv
Gastroenterol 2016;9:606-25. DOI PubMed PMC
78. Shealy NG, Yoo W, Byndloss MX. Colonization resistance: metabolic warfare as a strategy against pathogenic Enterobacteriaceae.
Curr Opin Microbiol 2021;64:82-90. DOI PubMed PMC
79. Duranti S, Gaiani F, Mancabelli L, et al. Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial
biomarkers. FEMS Microbiol Ecol 2016;92:fiw191. DOI
80. Li M, Ding J, Stanton C, et al. Bifidobacterium longum subsp. infantis FJSYZ1M3 ameliorates DSS-induced colitis by maintaining
the intestinal barrier, regulating inflammatory cytokines, and modifying gut microbiota. Food Funct 2023;14:354-68. DOI
81. Vazquez-Gutierrez P, De Wouters T, Werder J, Chassard C, Lacroix C. High iron-sequestrating bifidobacteria inhibit enteropathogen
growth and adhesion to intestinal epithelial cells in vitro. Front Microbiol 2016;7:1480. DOI PubMed PMC
82. Vito R, Conte C, Traina G. A multi-strain probiotic formulation improves intestinal barrier function by the modulation of tight and
adherent junction proteins. Cells 2022;11:2617. DOI PubMed PMC
83. Duranti S, Vivo V, Zini I, et al. Bifidobacterium bifidum PRL2010 alleviates intestinal ischemia/reperfusion injury. PLoS One
2018;13:e0202670. DOI PubMed PMC
84. Koninkx JF, Tooten PC, Malago JJ. Probiotic bacteria induced improvement of the mucosal integrity of enterocyte-like Caco-2 cells